Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
AssigneeOsaka University
InventorAtsushi KUMANOGOH
Life of this patent
Estimating the term…
Abstract
Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker.
Claims8
A method for screening a therapeutic agent for treating a cellular immune disease, the method comprising:
- (a) contacting a Sema3A polypeptide with eukaryotic cells expressing Neuropilin-1 and Plexin-A1, in the presence of a test substance;
- (b) measuring a signal produced by an interaction between the Sema3A polypeptide and the eukaryotic cells expressing Neuropilin-1 and Plexin-A1 in the presence of the test substance, and comparing the signal with a control signal produced by an interaction between the Sema3A polypeptide and the eukaryotic cells expressing Neuropilin-1 and Plexin-A1 in the absence of the test substance;
- and
- (c) selecting a test substance that reduces the signal in comparison to the control signal.
Dependencies are inferred from the claim text.